| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Susanne Meline last filed a Form 4 in August 2025, as Director at CLIR. The filings on record cover 4 companies. Susanne Meline's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 54,249 shares of CLIR. Net of sales, the CLIR filings show accumulation of 27,222 shares.
Susanne Meline has 28 Form 4 filings on record from February 2018 to August 2025, across 4 companies: Director at MDB Capital (MDBH), 2024–2025; Director at Catheter Precision (VTAK), 2021–2023; Director at ClearSign Technologies (CLIR), 2018–2023, and 1 more.
The 30 reported transactions were 18 option or other derivative awards, 6 stock awards, 3 open-market purchases and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $63K and no sales.
The largest open-market purchase was 22,222 shares of CLIR at an average $2.25 on February 27, 2018, about $50K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.